Brachytherapy with transperineal 125Iodine seeds for localized prostate cancer

被引:24
|
作者
Blank, LECM
Gonzalez, DG
de Reijke, TM
Dabhoiwala, NF
Koedooder, K
机构
[1] Acad Med Ctr, Dept Radiotherapy, NL-1100 DE Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Dept Urol, NL-1105 AZ Amsterdam, Netherlands
关键词
prostate cancer; (125)Iodine seeds; brachytherapy; radiotherapy;
D O I
10.1016/S0167-8140(00)00231-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background and purpose: To analyze the treatment results of transperineal (125)Iodine seeds in localized prostate cancer. Patients and methods: Between 1985 and 1996, 102 patients with T1-T2 NO prostate cancer were treated with transperineal (125)Iodine seed implants at the Academic Medical Centre in Amsterdam. Tumours were classified as T1c in four patients, T2a in 73 patients and T2b in 25 patients. The mean pre-treatment PSA was 17 ng/ml. The (125)Iodine seeds were implanted transperineally under transrectal ultrasound guidance. The mean prostate volume was 31 ml (range 15-48 ml). An average of 49 seeds (range 29-74) was implanted. The dose to the periphery of the prostate was 160 Gy. Until 1988, 27 patients had additional external pelvic irradiation to a dose of 40 Gy in 20 daily fractions of 2 Gy. Results: The 5- and 7-year actuarial survival rates were 77 and 63%, respectively (median 102 months). Ten patients (9.5%) died from prostate cancer. The 5- and 7-year clinical progression rates were 12 and 17%, respectively. Biochemical failure rates at 5 and 7 years were 39 and 44%, respectively. Age, alkaline phosphatase, creatinine, differentiation grade, additional treatment, staging procedure, number of seeds, prostate volume, treatment period and PSA were analyzed as prognostic factors. Only pre-treatment PSA was a prognosticator of clinical and biochemical outcome but not of survival. Biochemical control at 6 years varied from 30% for pre-treatment PSA values higher than 20 ng/ml to 95% for values less than or equal to 8 ng/ml. Forty-one out of 49 patients who were sexually active before brachytherapy maintained sexual function during the follow-up. Complete urinary incontinence occurred in one patient. No rectal complications were seen in patients receiving brachytherapy alone. Conclusions: Transperineal (125)Iodine seeds brachytherapy in localized prostate cancer achieves a good clinical control and overall survival with acceptable late toxicity. Biochemical failure was strongly correlated to the pre-treatment PSA value. (C) 2000 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:307 / 313
页数:7
相关论文
共 50 条
  • [1] Value of urinary flow rate in 125iodine transperineal prostate brachytherapy for localized prostate cancer
    Rosini, O., Jr.
    Muglia, R.
    Vignoli, L.
    Pinto, L. H.
    Feij, M.
    Vaz, F.
    Domenge, C.
    EJC SUPPLEMENTS, 2005, 3 (02): : 238 - 238
  • [2] Factors predicting for urinary morbidity following 125iodine transperineal prostate brachytherapy
    Williams, SG
    Millar, JL
    Duchesne, GM
    Dally, MJ
    Royce, PL
    Snow, RM
    RADIOTHERAPY AND ONCOLOGY, 2004, 73 (01) : 33 - 38
  • [3] Retrospective comparison of radical retropubic prostatectomy and 125iodine brachytherapy for localized prostate cancer
    Ramos, CG
    Carvalhal, GF
    Smith, DS
    Mager, DE
    Catalona, WJ
    JOURNAL OF UROLOGY, 1999, 161 (04): : 1212 - 1215
  • [4] Retrospective comparison of radical retropubic prostatectomy and 125iodine brachytherapy for localized prostate cancer -: Comment
    Reiter, R
    JOURNAL OF UROLOGY, 1999, 161 (04): : 1215 - 1215
  • [5] Transperineal 125iodine implantation for treatment of clinically localized prostate cancer:: 5-year tumor control and morbidity
    Storey, MR
    Landgren, RC
    Cottone, JL
    Stallings, JW
    Logan, CW
    Fraiser, LP
    Ross, CS
    Kock, RJ
    Berkley, LW
    Hauer-Jensen, M
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 43 (03): : 565 - 570
  • [7] Thyroid uptake of 125iodine after prostate permanent brachytherapy
    Chen, QS
    Blair, HF
    JOURNAL OF UROLOGY, 2004, 172 (05): : 1827 - 1829
  • [8] Prediction of urinary symptoms after 125iodine prostate brachytherapy
    Kelly, K
    Swindell, R
    Routledge, J
    Burns, M
    Logue, JP
    Wylie, JP
    CLINICAL ONCOLOGY, 2006, 18 (04) : 326 - 332
  • [9] EVALUATION OF DOSIMETRIC PARAMETERS AND DISEASE RESPONSE AFTER 125IODINE TRANSPERINEAL BRACHYTHERAPY FOR LOW- AND INTERMEDIATE-RISK PROSTATE CANCER
    Morris, W. James
    Keyes, Mira
    Palma, David
    McKenzie, Michael
    Spadinger, Ingrid
    Agranovich, Alex
    Pickles, Tom
    Liu, Mitchell
    Kwan, Winkle
    Wu, Jonn
    Lapointe, Vince
    Berthelet, Eric
    Pai, Howard
    Harrison, Robert
    Kwa, William
    Bucci, Joe
    Racz, Violet
    Woods, Ryan
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 73 (05): : 1432 - 1438
  • [10] Iodine-125 thin seeds decrease prostate swelling during transperineal interstitial permanent prostate brachytherapy
    Beydoun, Nadine
    Bucci, Joseph A.
    Chin, Yaw S.
    Malouf, David
    JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 2014, 58 (01) : 109 - 116